Benzinga | Nov 30, 2020 07:04AM EST

CTI BioPharma Announces Publication Of Article Highlighting Pacritinib Data From PAC203 Phase 2 Study In Myelofibrosis In Blood Advances

SEATTLE, Nov. 30, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that an article highlighting pacritinib data was published in Blood Advances. The article, titled "Determining the Recommended Dose of Pacritinib: Results from the PAC203 Phase 2 Dose-Finding Study in Patients with Advanced Myelofibrosis" is available online via this link.